Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000019.xml
Download PDF
Fortschr Neurol Psychiatr 2017; 85(02): 92-99
DOI: 10.1055/s-0042-119862
DOI: 10.1055/s-0042-119862
Originalarbeit
Prävalenz und Therapie bei Abhängigkeit von Methamphetamin („Crystal“)
Prevalence and Therapy of Crystal Methamphetamine DependenceFurther Information
Publication History
Publication Date:
24 February 2017 (online)
Zusammenfassung
Nach einem kurzen Überblick über Epidemiologie und Klinik von Missbrauch und Abhängigkeit von Amphetaminen und speziell „Crystal“ werden aktuelle Konzepte zur Behandlung von Crystal-Konsumenten und Ergebnisse der Therapieforschung dargestellt. Die Wirksamkeit zweier stationärer Therapiemodelle wird dabei in einer vom BMG geförderten Studie untersucht werden. Der Studienplan wird vorgestellt. Klinische Implikationen werden diskutiert.
Abstract
Following a short overview on the epidemiology and clinical correlates of amphetamine abuse and dependence, with special emphasis on metamphetamine (“crystal”), current treatment concepts and recent results of therapy research are discussed. The efficacy of two inpatient treatment models for methamphetamine dependence are currently studied in a study funded by the German Ministry of health. The study concept is given and possible implications are discussed.
-
Literatur
- 1 Soyka M. Hrsg. Drogennotfälle. Stuttgart: Schattauer; 2013
- 2 Soyka M. Medikamentenabhängigkeit. Stuttgart: Schattauer; 2016
- 3 Castells X. Ramos-Quiroga JA. Bosch R. et al. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Systematic Review 2011; 6: CD007813
- 4 Gouzoulis-Mayfrank E. Daumann J. Neurotoxicity of drugs of abuse – the case of methylenedioxyamphetamines (MDMA, extasy) and amphetamines. Dialogues Clin Neurosci 2009; 11: 305-317
- 5 Fleckenstein AE. Volz TJ. Riddle EL. et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007; 47: 681-698
- 6 Berman S. O’Neill J. Feres S. et al. Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 2008; 1141: 195-220
- 7 Seiden LS. Sabol KE. Metamphetamine and methxlendioxymetamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monograph 1996; 163: 251-276
- 8 Koester P. Volz KG. Tittgemeyer M. et al. Decision-making in polydrug amphetamine-type stimulant users: an fMRI study. Neuropsychopharmacology 2013; 38: 1377-1386
- 9 Daumann J. Koester P. Becker B. et al. Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. Neuroimage 2011; 54: 794-801
- 10 Simon SL. Dean AC. Cordova X. et al. Metamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 2010; 71: 335-344
- 11 Salo R. Nordahi TE. Buonocore MH. et al. Cognitive control and white matter callosal microstructure in metamphetamine-dependent subjects: a diffusion tensor imaging study. Biol Psychiatry 2009; 65: 122-128
- 12 Iversen L. Speed, Ecstasy, Ritalin. Amphetamine – Theorie und Praxis. Bern: Huber; 2009
- 13 Ersche KD. Turton AJ. Chamberlain SR. et al. Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry 2012; 169: 926-936
- 14 Hadamitzky M. McCunney S. Markou A. et al. Development of stereotyped behaviors during prolonged escalation of metamphetamine self-administration in rats. Psychopharmacology (Berl) 2012; 223: 259-269
- 15 Kalechstein AD. Newton TF. Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 2003; 15 (02) 215-220
- 16 Bramness JG. Gundersen OH. Guterstam J. et al. Amphetamine-induced psychosis – a separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry 2012; 12: 221
- 17 Grant KM. LeVan TD. Wells SM. et al. Methamphetamine-associates psychosis. Journal of Neuroimmune Pharmacology 2012; 7: 113-139
- 18 Harris D. Batki SL. Stimulant psychosis: symptom profile and acute clinical course. American Journal of Addiction 2000; 9: 28-37
- 19 Hsieh JH. Stein DJ. Howells FM. The neurobiology of methamphetamine induced psychosis. Frontiers in Human Neuroscience 2014; 8: 537
- 20 Lecomte T. Mueser KT. MacEwan W. et al. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. Journal of Nervous and Mental Diseases 2013; 201: 1085-1089
- 21 Soyka M. Sievers E. Fischer-Erlewein E. Amphetaminmissbrauch bei fraglichem adultem Aufmerksamkeitsdefizit/Hyperaktivitätssyndrom. Gesundheitswesen 2009; 71: 207-209
- 22 Gahr M. Freudenmanna RW. Hiemke C. et al. Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reaction. Psychiatry Research 2014; 215: 252-254
- 23 Vocci FJ. Montova ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry 2009; 22: 263-268
- 24 EMCDDA. Europäischer Drogenbericht. Lissabon: Europäische Beobachtungsstelle für Drogen und Drogensucht; 2015
- 25 United Nations Office on Drugs and Crime Vienna. World Drug Report. United Nations, New York, NY: 2013
- 26 Fusillo S. Misuse and diversion of stimulants for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 21-31
- 27 Wilens Timothy E. Adler Lenard A. Adams J. et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry 2008; 47 (01) 21-31
- 28 Wilens TE. Fusillo S. When ADHD and substance use disorders interact: relationship and treatment implications. Curr Psychiatry Rep 2007; 9: 408-414
- 29 Daumann J. Gouzoulis-Mayfrank E. Amphetamine, Ecstasy und Designerdrogen. Stuttgart: Kohlhammer; 2015
- 30 Neumann S. Franke AG. Soyka M. Methamphetaminkonsum in Deutschland – eine kurze Übersicht über Epidemiologie, Phänomenologie und Therapie. Nervenheilkunde (in Druck) 2016
- 31 Pabst A. Kraus L. Gomes de Matos E. et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321-331
- 32 Carson DS. Taylor ER. A growing methamphetamine dependence therapeutics graveyard. Addiction 2014; 109: 1887-1888
- 33 Galloway GP. Marinelli-casey P. Stalcup J. et al. Treatment as-usual in the methamphetamine treatment project. J Psychoactive Drugs 2000; 32: 165-175
- 34 Huber A. Ling W. Shoptaw S. et al. Integrating treatments for metamphetamine abuse: a psychosocial perspective. J Addict Dis 1997; 16: 41-50
- 35 Rawson RA. Shoptaw SJ. Obert JL. et al. An intensive outpatient approach for cocaine abuse treatment. The matrix model. J Subst Abuse Treat 1995; 12: 117-127
- 36 Rawson RA. Olbert JL. McCann MJ. et al. The Matrix Model Intensive Outpatient Alcohol and Drug Treatment Program: a 16-week Individualized Program. Center City, Minnesota: Hazelden; 2005
- 37 SAMSHA. Matrix Intensive Outpatient Treatment for People with Stimulant Use Disorders. Rockville, MD: U.S. Department of Health and Human Services; 2006
- 38 Pates R. Riley D. Eds Interventions for Amphetamine use. Riley publishers; 2010
- 39 Rawson RA. Marinelli-Casey P. Anglin MD. et al. A multi-site comparison of psychosocial approaches for the treatment of metamphetamine dependence. Addiction 1994; 99: 708-717
- 40 Baker A. Lee NK. Claire M. et al. Brief cognitive behavioral interventions for regular amphetamine users: a step in the right direction. Addiction 2005; 100: 367-378
- 41 Roll JM. Petry NM. Stitzer ML. et al. Contingency management for the treatment of methamphetamine use disorders. The American journal of psychiatry 2006; 163 (11) 1993-1999
- 42 Shoptaw S. Reback CJ. Peck JA. et al. Behavioral treatment approaches for metamphetamine dependence and HIV-related sexual risk behaviors among gay and bisexual men. Drug Alcohol Depend 2005; 78: 125-134
- 43 Luchansky B. Krupski A. Stark K. Treatment response by primary drug abuse: does metamphetamine make a difference?. J Subst Abuse Treat 2007; 32: 89-96
- 44 Polcin D. Bond J. Korcha R. et al. Randomized Trial of Intensive Motivational Interviewing for Metamphetamine dependence. J Addict Dis 2014; 33: 253-265
- 45 Petitjean SA. et al. A randomized controlled trial of combined cognitive-behavioral therapy plus prize-based contingency management for cocaine dependence. Drug Alcohol Depend 2014; 145: 94-100
- 46 Franke AG. Soyka M. Pharmakologisches Neuroenhancement aus Sicht der Suchtmedizin. Fortschr Neurol Psychiatr 2015; 83: 83-90
- 47 Bundeszentrale für gesundheitliche Aufklärung. Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2011. Köln: Bundeszentrale für gesundheitliche Aufklärung; 2012
- 48 Orth B. Piontec D. Kraus L. Illegale Drogen – Zahlen und Fakten zum Konsum. In: DH S. (Hrsg) Jahrbuch Sucht 2015. Lengerich: Pabst Science Publishers; 2015: 127-139
- 49 Hamdorf W. Susemihl I. Schacht-Jablonowsky M. Katamneseergebnisse der Entwöhnungsbehandlung bei amphetaminabhängigen Patienten. Sucht Aktuell 2015; 2: 43-46
- 50 Schoett K. Behandlung der Metamphetamin-Abhängigkeit. Suchtmedizin (in Druck) 2016
- 51 Drogenbeauftragte der Bundesregierung, Bundesministerium für Gesundheit (BMG), Bundesärztekammer (BÄK). S3-Leitlinie Methamphetamin-bezogene Störungen, Konsultationsfassung. 2016 Available from: www.crystal-meth.aezq.de
- 52 Obert JL. McCann MJ. Marinelli-Casey P. et al. The matrix model of outpatient stimulant abuse treatment: history and description. J Psychoactive Drugs 2000; 32: 157-164
- 53 Hamdorf W. et al. Crystal und Speed: Herausforderung für die Entwöhnungsbehandlung drogenabhängiger Menschen. Sucht Aktuell 2014; 21 (02) 46-48
- 54 Sucht DG. Dokumentationsstandards III für die Evaluation der Behandlung von Abhängigen. Sucht 2001 47 (Sonderheft 2)
- 55 Hautzinger M. Bailer M. Worall H. et al. BDI Beck-Depressions-Inventar Testhandbuch. 2., überarbeitete Auflage. Bern: Huber; 1995
- 56 Franke GH. SCL-90-R – Die Symptom-Checkliste von L. R. Derogatis (2. vollständig überarbeitete und neu normierte Auflage). Göttingen: Beltz; 2002
- 57 Nakovics H. Diehl A. Geiselhart H. et al. Entwicklung und Validierung eines Instrumentes zur substanzunabhängigen Erfassung von Craving: Die Mannheimer Craving Scale (MaCS). Psychiatrische Praxis 2009; 36 (02) 72-78
- 58 Borkenau P. Ostendorf F. NEO-FFI – NEO-FÜNF-FAKTOREN INVENTAR NACH COSTA UND MCCRAE – DEUTSCHE FASSUNG (PSYNDEX Tests Review) [NEO-Fünf-Faktoren-Inventar]. Göttingen: Hogrefe; 1993
- 59 Dutra L. Stathopoulou G. Basden SL. et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165: 179-187
- 60 Perngparn U. Lianonda B. Aramrattana A. et al. Metamphetamine dependence treatment rehabilitation in Thailand: a model assessment. J Med Assoc Thai 2011; 94: 11-117